{"id":"W4296017867","doi":"10.1016/j.annonc.2022.07.837","title":"713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Hepatocellular carcinoma; Placebo; Internal medicine; Oncology; Nuclear medicine; Urology; Immunotherapy; Pathology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001270819,0.0005900759,0.001676633,0.0003604161,0.0002987552,0.0007954862,0.0004024718,0.0007976328,0.006664934],"category_scores_gemma":[0.001198588,0.0002827707,0.001715558,0.0004001124,0.0003456621,0.0009238538,0.0004333449,0.001943407,0.0007761225],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006608964,"about_ca_system_score_gemma":0.000687803,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001382739,"about_ca_topic_score_gemma":0.002282568,"domain_scores_codex":[0.9995474,0.0001719085,0.00002812848,0.00008363517,0.00004353982,0.0001253557],"domain_scores_gemma":[0.9994298,0.0001779607,0.0001021261,0.00004942574,0.00003266085,0.0002081149],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9419258,0.003754939,0.002735404,0.0003413654,0.001381503,0.0000641303,0.00003368576,0.000599349,0.001959127,0.000125601,0.004182136,0.04289708],"study_design_scores_gemma":[0.6202312,0.2750795,0.08702336,0.000261267,0.005077776,0.0002282387,0.0001133976,0.001748261,0.002331852,0.0005830275,0.007258816,0.00006331321],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9718004,0.01012261,0.0004264215,0.001482182,0.0009429575,0.0007275321,0.007606478,0.0001121528,0.006779243],"genre_scores_gemma":[0.9847476,0.003512334,0.0004502362,0.001038328,0.0004045697,0.0005970401,0.004448724,0.00002376054,0.004777427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006664934,"threshold_uncertainty_score":0.02229643,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1141393283507759,"score_gpt":0.3312260680307059,"score_spread":0.21708673967993,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}